ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 7,290,000 shares, a drop of 8.8% from the March 15th total of 7,990,000 shares. Based on an average trading volume of 2,750,000 shares, the days-to-cover ratio is currently 2.7 days.

ADMA Biologics Price Performance

NASDAQ ADMA traded down $0.04 during trading hours on Monday, reaching $5.98. 1,814,382 shares of the company's stock were exchanged, compared to its average volume of 2,670,340. The firm has a fifty day moving average of $5.86 and a 200-day moving average of $4.69. ADMA Biologics has a one year low of $3.06 and a one year high of $6.76. The stock has a market cap of $1.36 billion, a PE ratio of -46.00 and a beta of 0.46. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The company had revenue of $73.90 million for the quarter, compared to analysts' expectations of $73.50 million. On average, equities research analysts predict that ADMA Biologics will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Mizuho increased their price target on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Cantor Fitzgerald raised their target price on ADMA Biologics from $6.50 to $8.00 and gave the stock an "overweight" rating in a research report on Thursday, February 29th. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $7.88.

Insiders Place Their Bets

In other news, Director Steve Elms sold 49,887 shares of the business's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $6.01, for a total transaction of $299,820.87. Following the sale, the director now directly owns 2,527,500 shares in the company, valued at $15,190,275. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 639,895 shares of company stock worth $3,927,169. 5.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP increased its holdings in shares of ADMA Biologics by 87.7% in the third quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company's stock valued at $867,000 after purchasing an additional 113,184 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in shares of ADMA Biologics by 22.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company's stock valued at $4,313,000 after acquiring an additional 224,696 shares during the period. American Century Companies Inc. boosted its holdings in ADMA Biologics by 20.8% in the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company's stock valued at $17,514,000 after acquiring an additional 840,761 shares during the last quarter. Aigen Investment Management LP acquired a new stake in ADMA Biologics in the third quarter worth about $140,000. Finally, SG Americas Securities LLC raised its holdings in ADMA Biologics by 417.3% during the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company's stock worth $421,000 after purchasing an additional 75,213 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.